Comparative evaluation of the efficacy of different marbofloxacin-based products in pigs at the nursery, growth and finish phases with clinical signs of respiratory disease: Zootecnia

• Autor(a) principal: Silva, Caio Abercio da
• Data de Publicação: 2023
• Outros Autores: Buzato, André Maurício, Romano, Gabriela Souza, Dias, Cleandro Pazinato, Souza, Kelly Lais, Callegari, Marco Aurélio, Carvalho, Rafael Humberto
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Semina. Ciências Agrárias (Online)
• Texto Completo: https://ojs.uel.br/revistas/uel/index.php/semagrarias/article/view/46430
• topic: Antibiotics; Performance; Pneumonia; Cough.; Antibióticos; Desempenho; Pneumonia; Tosse.

Marbofloxacin is one of the antibiotics of choice for the treatment of pigs with clinical manifestations of respiratory disease. Some commercial products on the market contain this active ingredient, and the objective of this study was to evaluate the efficacy of 3 available marbofloxacin-based products based on the SISAAB (single injection and short-term antibiotic) concept with regard to the performance and health parameters of pigs in the nursery, growth and termination phases with clinical manifestations of respiratory disease (RD). A total of 78 animals with clinical manifestations of RD from a total of 1726 pigs were used. The animals that had RD symptoms were weighed, identified and randomly subjected to 3 treatments: T1 - Forcyl® (n = 27); T2 - Marbox® (n = 25); T3 - Resolutor® (n = 26). All treatments corresponded to a single intramuscular dose of 8 mg of marbofloxacin per kg of live weight. After treatment, clinical signs of cough and depression, water consumption, rectal temperature, performance parameters, lung lesions and the pneumonia index of the animals were evaluated. The animals that received T1 and T3 maintained a mean rectal temperature of 39.38 °C 2 days after administration. In contrast, animals in the group that received T2 had significantly higher temperatures (p = 0.068) in this period (39.53 °C). There was a greater decrease in temperature (p = 0.042) in the 24 hours after drug administration in animals that received T1 (-0.573 °C). Regarding the other performance parameters, clinical signs of cough and depression, water consumption, lung injury and the pneumonia index, no differences were observed between the marbofloxacin-based products evaluated (p > 0.05). All marbofloxacin-based products were effective in reducing the clinical signs of RD and promoting animal performance and health. However, T1 was more effective in reducing the rectal temperature of the animals.